French CAR-T biotech Mnemo Ther­a­peu­tics shut­ters US op­er­a­tions

A Sofinno­va-backed CAR-T mak­er has shut down its New York and Prince­ton, NJ sites and will con­tin­ue op­er­at­ing out of its Paris hub.

Mnemo Ther­a­peu­tics turned the lights off at its US op­er­a­tions ef­fec­tive im­me­di­ate­ly on Feb. 23, ac­cord­ing to em­ploy­ees’ posts on LinkedIn and con­fir­ma­tion from co-founder and op­er­at­ing chief Alain Maiore.

“When Se­bas­t­ian [Amigore­na] and I start­ed Mnemo Tx, we were look­ing to build a com­pa­ny where the hu­man val­ue of ‘stand­ing shoul­der to shoul­der’ in dif­fi­cult time would typ­i­fy the DNA of our teams across the ocean,” Maiore wrote on LinkedIn in re­cent days. “The de­ci­sion we had to make about shut­ting down our US op­er­a­tions, to move back our CT ef­fort to Eu­rope, next to our tar­get dis­cov­ery plat­form was a very dif­fi­cult one.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.